The RAS-RAF-MEK-ERK pathway is activated in a variety of tumors, including MM [20,50]; therefore, RAS-RAF-MEK-ERK pathway inhibitors are promising therapeutic options for cancer therapy. This evidence concerns the gene MAP2K7 and cancer.